Dirocaftor

DB16143InvestigationalSmall molecule

Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₂₂H₂₈N₂O₃Si₂ · 424.647 g/mol (avg)
Code names: PTI-808

Resolves to

Compound

UNII2G3T6M1AS9CAS2137932-23-9

Structure

InChIKeyTYQIFWXBQYAKCR-UHFFFAOYSA-NSMILESC[Si](C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=C(C=CC=C2)C1=O)[Si](C)(C)C

Targets

P13569CFTR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dirocaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account